Lymphoma Trial, Recruiting (NCT07233720)

Lymphoma Trial, Recruiting NCT07233720 Sponsor: Henan Cancer Hospital Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT07233720 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with a type of lymphoma called CD20-positive marginal zone lymphoma, confirmed by a tissue sample test
People whose first treatment plan involves a combination of two specific drugs: zanubrutinib and rituximab
People who have not received any systemic (whole-body) treatment for this condition before joining the study
People who have at least one measurable area of disease — meaning a lymph node lesion larger than 1.5 cm or a lesion outside the lymph nodes larger than 1.0 cm, as seen on a CT scan
People who are willing to participate, have signed a consent form, and are able to attend follow-up appointments as required

Who may not be able to join:

People who have a history of another cancer, or who currently have another active cancer that requires treatment
People who are receiving any other anti-cancer drug treatments at the same time as zanubrutinib and rituximab (note: steroid medications taken to manage symptoms before formal treatment begins may be an exception — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 12 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhihua Yao, M.D. Ph.D, Henan Cancer Hospital

Phone: +8613592622292

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07233720

Sponsor: Henan Cancer Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: +8613592622292

More information: https://clinicaltrials.gov/study/NCT07233720

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with a type of lymphoma called CD20-positive marginal zone lymphoma, confirmed by a tissue sample test
People whose first treatment plan involves a combination of two specific drugs: zanubrutinib and rituximab
People who have not received any systemic (whole-body) treatment for this condition before joining the study
People who have at least one measurable area of disease — meaning a lymph node lesion larger than 1.5 cm or a lesion outside the lymph nodes larger than 1.0 cm, as seen on a CT scan
People who are willing to participate, have signed a consent form, and are able to attend follow-up appointments as required

Who may not be able to join:

People who have a history of another cancer, or who currently have another active cancer that requires treatment
People who are receiving any other anti-cancer drug treatments at the same time as zanubrutinib and rituximab (note: steroid medications taken to manage symptoms before formal treatment begins may be an exception — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 12 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Henan Cancer Hospital

Registry

ClinicalTrials.gov

Start date

18 November 2025

Est. completion

1 June 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

complete response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov